Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Survival of Glioblastoma
share announcement

Advances in Survival of Glioblastoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 1 June 2024 | Viewed by 2263

Special Issue Editors

Dr. Ondrej Kalita

E-Mail Website
Guest Editor
1. Department of Neurosurgery, Faculty of Medicine and Dentistry, Palacky University in Olomouc—University Hospital, Olomouc, Czech Republic
2. Department of Health Care Science, Faculty of Humanities, T. Bata University in Zlin, Zlin, Czech Republic
Interests: glioblastoma
Dr. Tomas Kazda

E-Mail Website
Guest Editor
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Interests: brain metastases; radiosurgery; intensity modulated radiation therapy

Special Issue Information

Dear Colleagues,

Glioblastoma (GBM) is the most common malignant brain tumor in adults and has a poor prognosis with near-inevitable recurrence. Many medical teams around the world strive for the substantial prolongation of GBM patients’ life expectancy and improving their quality of life.

Aggressive multimodal therapy that involves maximally radical and safe tumor resection followed by the Stupp oncotherapy protocol has yielded the best treatment outcomes. Preoperative and intraoperative imaging tools and techniques such as MRI, Raman spectroscopy, fluorescence-guided surgery, awake surgery and intraoperative brain mapping have made it possible to maximize tumor cytoreduction and minimize surgical morbidity during neurosurgery, improving GBM patients’ life expectancy. This can also be followed by oncotherapy, including different radiotherapeutic (stereotactic radiotherapy, intensity-modulated radiotherapy, image-guided radiotherapy, hypofractionated schedules, etc.), tumor-treating-field (TTF) techniques, label or off-label systemic therapy (immune checkpoint inhibitors, PARP inhibitor, adaptive T-cell therapy, topoisomerase inhibitor, autologous dendritic cells, FASN inhibitor, PI3K/mTOR inhibitor, VEGFR2-TIE2 tyrosine kinase inhibitor, JAK1/3 inhibitor, oncolytic viruses, peptide vaccines, etc.), in the attempt to change GBM patients’ destiny.

The rate of increase in patient survival at the beginning of the temozolomid era was gradually slow and has plateaued in the last 5–10 years.

This Special Issue will present and share ideas, philosophy and experiences about GBM treatment, focused on advanced treatment strategies.

Dr. Ondrej Kalita
Dr. Tomas Kazda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • oncotherapy
  • life expectancy
  • overall survival
  • quality of life

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 254 KiB  
Article
Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients
by Hanah Hadice Gull, Antonia Carlotta Von Riegen, Greta Theresa Beckmann, Pikria Ketelauri, Sebastian Walbrodt, Alejandro N. Santos, Christoph Oster, Teresa Schmidt, Martin Glas, Ramazan Jabbarli, Neriman Özkan, Philipp Dammann, Björn Scheffler, Ulrich Sure and Yahya Ahmadipour
Cancers 2024, 16(6), 1231; https://doi.org/10.3390/cancers16061231 - 21 Mar 2024
Viewed by 735
Abstract
(1) Background: Although the incidence of glioblastoma (GB) has a peak in patients aged 75–84 years, no standard treatment regimen for elderly patients has been established so far. The goal of this study was to analyze the outcome of GB patients ≥ 65 [...] Read more.
(1) Background: Although the incidence of glioblastoma (GB) has a peak in patients aged 75–84 years, no standard treatment regimen for elderly patients has been established so far. The goal of this study was to analyze the outcome of GB patients ≥ 65 years to detect predictors with relevant impacts on overall survival (OS) and progression-free survival (PFS). (2) Methods: Medical records referred to our institution from 2006 to 2020 were analyzed. Adult GB patients with clinical data, postoperative MRI data, and ≥1 follow-up investigation after surgical resection were included. The complete cohort was divided into a younger (<65) and an elderly group (≥65 years). Multiple factors regarding OS and PFS were scanned using univariate and multivariable regression with p < 0.05. (3) Results: 1004 patients were included with 322 (61.0%) male individuals in the younger and 267 (56.1%) males in the older cohort. The most common tumor localization was frontal in both groups. Gross total resection (GTR) was the most common surgical procedure in both groups, followed by subtotal resection (STR) (145; 27.5%) in the younger group, and biopsy (156; 32.8%) in the elderly group. Multivariate analyses detected that in the younger cohort, MGMT promoter methylation and GTR were predictors for a longer OS, while MGMT methylation, GTR, and hypofractionated radiation were significantly associated with a longer OS in the elderly group. (4) Conclusions: Elderly patients benefit from surgical resection of GB when they show MGMT promoter methylation, undergo GTR, and receive hypofractionated radiation. Furthermore, MGMT methylation seems to be associated with a longer PFS in elderly patients. Further investigations are required to confirm these findings, especially within prospective radiation therapy studies and molecular examinations. Full article
(This article belongs to the Special Issue Advances in Survival of Glioblastoma)

Review

Jump to: Research

15 pages, 293 KiB  
Review
Rehabilitation in People Living with Glioblastoma: A Narrative Review of the Literature
by Anna Zanotto, Rebecca N. Glover, Tobia Zanotto and Florien W. Boele
Cancers 2024, 16(9), 1699; https://doi.org/10.3390/cancers16091699 - 27 Apr 2024
Viewed by 797
Abstract
Glioblastoma is the most common primary malignant brain tumor. While preliminary data point to the positive effects of rehabilitation for patients with glioblastoma, there are unique challenges for clinicians working with this population, including limited life expectancy and/or rapid neurological deterioration. The aim [...] Read more.
Glioblastoma is the most common primary malignant brain tumor. While preliminary data point to the positive effects of rehabilitation for patients with glioblastoma, there are unique challenges for clinicians working with this population, including limited life expectancy and/or rapid neurological deterioration. The aim of this article is to review the literature on rehabilitation of adults with glioblastoma, including the feasibility of interventions, their effectiveness, as well as the current clinical practice. The reviewed literature suggests that rehabilitation has been found beneficial for improving the functional prognosis and quality of life of adults with glioblastoma and is desired by patients. We summarize the qualitative evidence regarding healthcare professionals’ and patients’ perspectives on the use of supportive care services. We conclude there is a need for the design of effective rehabilitation programs for patients with glioblastoma, as well as for the development of glioblastoma-specific clinical guidelines for rehabilitation practitioners. Full article
(This article belongs to the Special Issue Advances in Survival of Glioblastoma)
19 pages, 862 KiB  
Review
Pentraxin 3: A Main Driver of Inflammation and Immune System Dysfunction in the Tumor Microenvironment of Glioblastoma
by Sarah Adriana Scuderi, Alessio Ardizzone, Ayomide Eniola Salako, Giuseppe Pantò, Fabiola De Luca, Emanuela Esposito and Anna Paola Capra
Cancers 2024, 16(9), 1637; https://doi.org/10.3390/cancers16091637 - 24 Apr 2024
Viewed by 338
Abstract
Brain tumors are a heterogeneous group of brain neoplasms that are highly prevalent in individuals of all ages worldwide. Within this pathological framework, the most prevalent and aggressive type of primary brain tumor is glioblastoma (GB), a subtype of glioma that falls within [...] Read more.
Brain tumors are a heterogeneous group of brain neoplasms that are highly prevalent in individuals of all ages worldwide. Within this pathological framework, the most prevalent and aggressive type of primary brain tumor is glioblastoma (GB), a subtype of glioma that falls within the IV-grade astrocytoma group. The death rate for patients with GB remains high, occurring within a few months after diagnosis, even with the gold-standard therapies now available, such as surgery, radiation, or a pharmaceutical approach with Temozolomide. For this reason, it is crucial to continue looking for cutting-edge therapeutic options to raise patients’ survival chances. Pentraxin 3 (PTX3) is a multifunctional protein that has a variety of regulatory roles in inflammatory processes related to extracellular matrix (ECM). An increase in PTX3 blood levels is considered a trustworthy factor associated with the beginning of inflammation. Moreover, scientific evidence suggested that PTX3 is a sensitive and earlier inflammation-related marker compared to the short pentraxin C-reactive protein (CRP). In several tumoral subtypes, via regulating complement-dependent and macrophage-associated tumor-promoting inflammation, it has been demonstrated that PTX3 may function as a promoter of cancer metastasis, invasion, and stemness. Our review aims to deeply evaluate the function of PTX3 in the pathological context of GB, considering its pivotal biological activities and its possible role as a molecular target for future therapies. Full article
(This article belongs to the Special Issue Advances in Survival of Glioblastoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop